Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age-Reference-Cited by-同舟云学术

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age

Published:2020-01 Issue:3 Volume:38 Page:530-538
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Bravo Lulu C.,Carlos Josefina C.,Gatchalian Salvacion R.,Montellano May Emmeline B.,Tabora Charissa Fay Corazon B.,Thierry-Carstensen Birgit,Tingskov Pernille Nyholm,Sørensen Charlotte,Wachmann Henrik,Bandyopadhyay Ananda S.^ORCID,Nielsen Pernille Ingemann,Kusk Mie Vestergaard

Funder

Bill & Melinda Gates Foundation, Seattle, WA, USA

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. World Health Organization (WHO). Poliomyelitis.. 2019. Accessed 27Mar2019. https://www.who.int/en/news-room/fact-sheets/detail/poliomyelitis.

2. World Health Organization (WHO). Polio eradication & endgame strategic plan 2013-2018. Geneva, Switzerland. WHO Press World Health Organization; 2013. Accessed 27Mar2019. http://polioeradicationorg/who-we-are/strategy/.

3. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication;Minor;Vaccine,2009

4. Poliovirus vaccination options for achieving eradication and securing the endgame;Estivariz;Current Opin Virol,2013

5. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats;Andreasen;Vaccine,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India;Vaccines;2024-04-17

2. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines;Inflammopharmacology;2024-02-03

3. Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study;Vaccine;2023-03

4. Poliovirus Vaccine—Inactivated;Plotkin's Vaccines;2023

5. Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication;Human Vaccines & Immunotherapeutics;2022-12-28